All In Biotech

Drug Trial Radar · NCT01360866

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial

Last checked: Nov 19, 2026Latest source record: Sep 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,944

Actual

Start

Oct 2011

Primary completion

Apr 18, 2017

Study completion May 18, 2017

Sponsor

Sponsor type
Industry
First posted
May 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)

Conditions

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders

Interventions

  • OPC-34712Drug

    Tablet

  • EscitalopramDrug

    Tablet

  • FluoxetineDrug

    Capsule

  • Paroxetine CRDrug

    Controlled-release tablets

  • SertralineDrug

    Tablets

  • DuloxetineDrug

    Delayed-release capsules

  • Venlafaxine XRDrug

    Extended-release capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs) - All ParticipantsTime frame: From screening to week 52/early termination

Locations

142 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Beverly Hills, California

  • Research Site

    Costa Mesa, California

  • Research Site

    Glendale, California

  • Research Site

    Irvine, California

  • Research Site

    Oceanside, California

  • Research Site

    Redlands, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    Santa Ana, California

  • Research Site

    Sherman Oaks, California

  • Research Site

    Temecula, California

  • Research Site

    Upland, California

  • Research Site

    Norwalk, Connecticut

  • Research Site

    Coral Gables, Florida

  • Research Site

    Coral Springs, Florida

  • Research Site

    Fort Myers, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jacksonville Beach, Florida

  • Research Site

    Melbourne, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami Springs, Florida

  • Research Site

    Oakland Park, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    The Villages, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Alpharetta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Smyrna, Georgia

  • Research Site

    Oak Brook, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Lafayette, Indiana

  • Research Site

    Prairie Village, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Lake Charles, Louisiana

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.